A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients With Type I Diabetes
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Exenatide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 06 Aug 2019 Status changed from active, no longer recruiting to completed.
- 08 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 May 2019.
- 17 Jan 2019 Planned End Date changed from 1 Aug 2018 to 1 Feb 2019.